Subsidiary product Fluorouracil Injection of Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) receives approval from the US FDA.

Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that its subsidiary, Jianjin Pharmaceutical Co., Ltd. ("Jianjin Pharmaceutical"), recently received approval notification for the ANDA of Fluorouracil Injection, 2.5g/50mL (50mg/mL) pharmacy bulk package issued by the U.S. Food and Drug Administration (hereinafter referred to as "FDA"). The newly approved product is expected to be launched in the U.S. market soon, which is likely to have a positive impact on the company's business performance. This product is used for the treatment of breast and digestive system (colon, rectum, stomach, pancreas) gland cancer. According to the investigation, there are currently six generic versions of Fluorouracil Injection, 2.5g/50mL (50mg/mL) marketed in the U.S. by Accord Healthcare Inc, Alembic Pharmaceuticals Ltd, Eugia Pharma Specialities Ltd, Fresenius Kabi Usa Llc, Gland Pharma Ltd, and Sagent Pharmaceuticals Inc.